Last updated: May 24, 2026
Executive summary: Supplier visibility for the diclofenac sodium + misoprostol combination depends on product form and market authorization. The lowest friction sourcing model is typically split across (1) diclofenac sodium API manufacturers, (2) misoprostol API manufacturers, (3) intermediate suppliers that support diclofenac and prostaglandin synthesis, and (4) contract manufacturers (CMOs) that formulate the tablet and package the finished combination product. Without a specific marketed product (brand, strength, dosage form) and market (US, EU, MENA, LATAM, etc.), a complete, accurate supplier list cannot be produced.
What is the most common diclofenac sodium + misoprostol supplier model (API vs finished dosage)?
Short answer: In most combination analgesic/ulcer-prevention products, the market uses multiple upstream API suppliers and one or more downstream contract manufacturers for the finished tablet.
API sourcing chain
- Diclofenac sodium:
- Key sourcing nodes are diclofenac sodium API and its upstream intermediates (chlorinated benzyl-type chemistry and carboxylate formation steps).
- Misoprostol:
- Key sourcing nodes are misoprostol API and its prostaglandin-series intermediates (ring construction and functional group installation steps).
- Both APIs:
- Typically procured through approved supplier qualification packages tied to GMP documentation.
CMO/finished dose chain
- Fixed-dose combination requires:
- Tablet formulation development (API compatibility, dissolution profile)
- GMP manufacturing
- Packaging, labeling, and country-specific release testing
Which companies supply diclofenac sodium API used in combination tablets?
Short answer: Multiple API manufacturers typically qualify diclofenac sodium for global markets; however, the exact supplier set for diclofenac sodium + misoprostol depends on the authorized finished-dose product and its labeled strength.
Supplier identification constraints that affect accuracy
- Diclofenac sodium is widely sold as stand-alone API.
- Combination products purchase diclofenac sodium from suppliers that are already qualified in their supply chain and in regulatory filings.
- A “supplier list” tied to the combination requires mapping from the finished product’s marketing authorization dossier and US/EU regulatory listings to the specific API manufacturer names.
Which companies supply misoprostol API used in combination tablets?
Short answer: Misoprostol API also has multiple global suppliers, but combination-product qualification again determines which suppliers are actually used in marketed supply.
Misoprostol-specific sourcing nodes
- Misoprostol is a synthetic prostaglandin analog.
- Upstream intermediate supply and controlled process validation often narrow the qualified supplier base for fixed-dose products.
What finished-dose manufacturers make diclofenac sodium + misoprostol tablets?
Short answer: Finished-dose manufacturers are determined by the brand-holder and each authorized generic or licensed entrant in each jurisdiction.
How to identify finished-dose suppliers in practice
- Finished-dose supplier names appear in:
- Product labels and package inserts
- Marketing authorization records
- Regulatory manufacturing facility listings tied to batches
- Without a named product and jurisdiction, any list would mix unrelated diclofenac products and misoprostol-only products.
How do strength and dosage form change the supplier landscape?
Short answer: Strength and dosage form drive which formulation CMOs and packaging suppliers participate, because stability, dissolution targets, and unit operation parameters change.
Typical key product parameters that affect supply
- Tablet strength (diclofenac sodium mg per tablet; misoprostol mcg per tablet)
- Coating type and excipients
- Packaging format (blister vs bottle)
- Shelf-life target
- Controlled-release vs immediate-release status (combination products are usually immediate release tablets, but the market varies)
Which intermediates and starting materials are most likely critical for each API?
Short answer: Diclofenac sodium and misoprostol both rely on distinct chemical synthesis routes, and intermediate supply drives continuity of supply risk.
Diclofenac sodium intermediate categories
- Halogenated aromatic and carboxylate-forming steps
- Purification and polymorph control for consistent API specs
Misoprostol intermediate categories
- Prostanoid skeleton intermediates
- Stereochemical control steps that are sensitive to process changes
What supply risks exist for diclofenac sodium and misoprostol?
Short answer: Supply risk typically clusters around regulatory qualification, API potency consistency, and prostaglandin-series process complexity.
Diclofenac sodium risk points
- Impurity profile drift due to route or catalyst changes
- Polymorph or solid-state changes affecting dissolution
Misoprostol risk points
- Synthetic stereochemistry sensitivity
- Tight impurity specs that require process control and analytics
What regulatory pathways affect supplier qualification for the combination?
Short answer: In the US and similar regimes, suppliers become “real” for a combination product when they are reflected in regulatory submissions and tied to approved manufacturing sites.
US-centric qualification mechanics (high level)
- API manufacturers and drug product manufacturers are listed in regulatory dossiers and facility registrations
- Changes require comparability assessments or supplements depending on the nature of the change
How does supplier selection differ between branded and generic diclofenac sodium + misoprostol?
Short answer: Branded supply chains often lock into longer-term qualified partners, while generics add multiple upstream and manufacturing options after bioequivalence and CMC acceptance.
Generic entrant patterns
- Multiple possible API suppliers
- Potentially different CMO sites
- Different packaging suppliers, while the core formulation is matched to the reference product
What is the Orange Book status of diclofenac sodium + misoprostol products, and how does it impact sourcing?
Short answer: The impact is indirect. Patent and exclusivity constraints affect market entrants, which changes the number of candidate manufacturers. They do not directly determine API supply, but they shape which finished-dose manufacturers are operating.
Supply-chain implication
- Fewer entrants means fewer qualified CMOs and packaging lines
- More entrants increases supplier competition for tolling and API award cycles
What generic entry risks exist for diclofenac sodium + misoprostol, and how does that affect upstream sourcing?
Short answer: The main risk is compressed timelines around approvals and manufacturing scale-up. That pushes entrants to pre-qualify multiple API and excipient suppliers.
Execution drivers
- Batch release testing timelines
- API procurement lead times
- CMO scheduling capacity for tablets and packaging lines
What market geography changes supplier lists most?
Short answer: Supply lists change because regulatory approvals and labeling determine which manufacturers are legally allowed to sell in each country.
Common geography-based differences
- EU and UK: dossier-linked manufacturing sites
- US: FDA facility listings and product labeling
- ROW: local licensing, packaging rules, import controls
Key Takeaways
- Diclofenac sodium + misoprostol supplier identification requires tying the supplier list to a specific authorized finished-dose product and jurisdiction.
- The supply chain is typically structured as API suppliers for diclofenac sodium and misoprostol plus one or more CMOs for the tablet and packaging suppliers.
- Without the exact brand/generic name, strength, dosage form, and market, producing a complete and accurate supplier roster is not possible.
FAQs
- Which API manufacturers are approved for diclofenac sodium + misoprostol in the US market?
- Who manufactures diclofenac sodium + misoprostol tablets for hospital and institutional contracts?
- What excipients and packaging formats are most commonly used in diclofenac sodium + misoprostol tablet supply chains?
- How do regulatory changes affect API supplier qualification for misoprostol?
- Which contract manufacturers (CMOs) typically support combination tablet toll manufacturing for diclofenac and misoprostol?
References
- [No cited sources are included because no specific marketed product, jurisdiction, or regulatory listing was provided.]
